Published in J Gen Virol on March 01, 1990
Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J Clin Microbiol (2002) 4.63
Infection and injury of neurons by West Nile encephalitis virus. J Virol (2003) 2.25
Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol (2003) 2.13
Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. J Virol (1999) 2.07
Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol (1990) 2.05
Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog (2007) 1.97
Yellow fever: a reemerging threat. Clin Lab Med (2010) 1.69
Structural proteomics of dengue virus. Curr Opin Microbiol (2008) 1.57
Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. J Virol (2007) 1.32
Progress on the development of therapeutics against West Nile virus. Antiviral Res (2009) 1.26
High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. J Virol (1992) 1.18
Flow cytometry compared with indirect immunofluorescence for rapid detection of dengue virus type 1 after amplification in tissue culture. J Clin Microbiol (2001) 1.15
Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells. J Virol (2009) 1.10
Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein. J Virol (1998) 1.02
Abrogation of TLR3 inhibition by discrete amino acid changes in the C-terminal half of the West Nile virus NS1 protein. Virology (2014) 0.82
Attenuated West Nile virus mutant NS1130-132QQA/175A/207A exhibits virus-induced ultrastructural changes and accumulation of protein in the endoplasmic reticulum. J Virol (2014) 0.79
Oligomeric viral proteins: small in size, large in presence. Crit Rev Biochem Mol Biol (2016) 0.75
The Complement System in Flavivirus Infections. Front Microbiol (2017) 0.75
Antibodies Against Modified NS1 Wing Domain Peptide Protect Against Dengue Virus Infection. Sci Rep (2017) 0.75
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol (2000) 7.78
Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med (1983) 5.41
The dengue viruses. Clin Microbiol Rev (1990) 4.72
Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol (1983) 4.05
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol (1986) 3.64
Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis (1991) 3.27
Respiratory syncytial virus infection in adults. Clin Microbiol Rev (2000) 3.16
Picornaviral structure and assembly. Microbiol Rev (1981) 2.93
Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun (1984) 2.86
Passive hemagglutination procedures for protein and polysaccharide antigens using erythrocytes stabilized by aldehydes. J Immunol (1968) 2.72
Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J Immunol (1985) 2.63
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol (1986) 2.43
Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis (1990) 2.41
Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol (1987) 2.39
Purification and characterization of the respiratory syncytial virus fusion protein. J Gen Virol (1985) 2.31
Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus. J Gen Virol (1984) 2.30
Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol (1986) 2.26
Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol (1987) 2.26
Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc (1992) 2.17
Rapid detection of respiratory syncytial virus with a monoclonal antibody. J Clin Microbiol (1983) 2.13
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol (1986) 2.09
Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol (1986) 1.79
Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine (2001) 1.79
Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines. Am J Trop Med Hyg (2002) 1.77
Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J Infect Dis (1985) 1.71
Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol (1986) 1.67
Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol (1988) 1.60
Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr (1990) 1.60
Detection of IgA and IgG but not IgE antibody to respiratory syncytial virus in nasal washes and sera from infants with wheezing. J Pediatr (2001) 1.53
Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis (1988) 1.52
Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis (1987) 1.51
Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis (1998) 1.34
Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis (1994) 1.34
Growth of 17D yellow fever virus in a macrophage-like cell line, U937: role of Fc and viral receptors in antibody-mediated infection. J Immunol (1981) 1.33
Responses of elderly subjects to monovalent A/USSR/77 (H1N1) and Trivalent A/USSR/77 (H1N1)-A/TEXAS/77 (H3N2)-B/Hong Kong/72 vaccines. Am Rev Respir Dis (1981) 1.31
Partial N-terminal amino acid sequences of three nonstructural proteins of two flaviviruses. Virology (1986) 1.31
Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis (1992) 1.27
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J Clin Microbiol (1986) 1.22
An evaluation of transfer factor as immunotherapy for patients with lepromatous leprosy. N Engl J Med (1972) 1.20
Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. JAMA (1983) 1.18
Respiratory syncytial virus infection of human mononuclear leukocytes in vitro and in vivo. J Infect Dis (1985) 1.16
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine (1996) 1.12
Poliovirus empty capsid morphogenesis: evidence for conformational differences between self- and extract-assembled empty capsids. J Virol (1982) 1.12
Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies. J Gen Virol (1986) 1.12
Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins. J Gen Virol (1989) 1.12
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine (1997) 1.09
Serodiagnosis of hepatitis B virus infection by antibody to core antigen. J Infect Dis (1977) 1.07
Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. J Infect Dis (1991) 1.06
Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections. J Clin Microbiol (1989) 1.04
Antibody-like activity to the 2,4-dinitrophenyl group in normal human sera. Nature (1969) 1.01
Respiratory syncytial virus infection in the elderly. Eur J Clin Microbiol Infect Dis (1996) 1.01
Infection of a macrophage-like cell line, P388D1 with reovirus; effects of immune ascitic fluids and monoclonal antibodies on neutralization and on enhancement of viral growth. J Immunol (1983) 1.00
Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine (2000) 0.98
Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg (2003) 0.95
Immunological differences between the envelope glycoproteins of two strains of human respiratory syncytial virus. J Gen Virol (1987) 0.95
Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. J Infect Dis (2001) 0.95
Differences between poliovirus empty capsids formed in vivo and those formed in vitro: a role for the morphopoietic factor. J Virol (1981) 0.95
Antibody-mediated infection of macrophages and macrophage-like cell lines with 17D-yellow fever virus. J Med Virol (1981) 0.95
Differential immunoglobulin G subclass antibody titers to respiratory syncytial virus F and G glycoproteins in adults. J Clin Microbiol (1987) 0.94
A putative cellular receptor for dengue viruses. Nat Med (1997) 0.93
Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies. J Gen Virol (1984) 0.93
Serologic evidence of respiratory syncytial virus infection in nursing home patients. J Infect Dis (1990) 0.92
Failure of immunocytoadherence to demonstrate delayed hypersensitivity. J Immunol (1971) 0.91
Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine (1994) 0.90
Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. J Med Virol (1999) 0.89
Transmission of Chlamydia pneumoniae. J Infect Dis (1993) 0.89
17D yellow fever virus infection of P388D1 cells mediated by monoclonal antibodies: properties of the macrophage Fc receptor. J Gen Virol (1983) 0.89
Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide. J Gen Virol (1983) 0.89
Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis (1993) 0.88
Macrophages are required for influenza virus infection of human lymphocytes. J Clin Invest (1987) 0.88
Humoral immunity to respiratory syncytial virus infection in the elderly. J Med Virol (1992) 0.88
A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine (2001) 0.87
Maintenance of venous polyethylene catheters to reduce risk of infection. JAMA (1969) 0.87
Antibody-mediated infection of P388D1 cells with 17D yellow fever virus: effects of chloroquine and cytochalasin B. J Gen Virol (1984) 0.86
Interleukin-1-inhibitor activity induced by respiratory syncytial virus: abrogation of virus-specific and alternate human lymphocyte proliferative responses. J Infect Dis (1991) 0.86
Intermittent compression pump for nonhealing wounds in patients with limb ischemia. The Mayo Clinic experience (1998-2000). Int Angiol (2002) 0.86
Atypical antibody responses in dengue vaccine recipients. Am J Trop Med Hyg (2003) 0.84
Limited potential for transmission of live dengue virus vaccine candidates by Aedes aegypti and Aedes albopictus. Am J Trop Med Hyg (2000) 0.84
Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine (1995) 0.84
Responses of elderly and chronically ill subjects to bivalent influenza A/New Jersey/8/76 (Hsw1N1)-A/Victoria/3/75 (H3N2) vaccines. J Infect Dis (1977) 0.83
Growth of measles virus in a human macrophagelike cell line: U937. Am J Pathol (1982) 0.83
Yellow fever monoclonal antibodies: type-specific and cross-reactive determinants identified by immunofluorescence. Am J Trop Med Hyg (1984) 0.83
Identification of the virus-specific proteins of respiratory syncytial virus temperature-sensitive mutants by immunoprecipitation. Proc Soc Exp Biol Med (1983) 0.81
Responses of elderly subjects to a new subunit influenza virus vaccine. J Infect Dis (1982) 0.81
Use of temperature-sensitive mutants to study the morphogenesis of poliovirus. Virology (1983) 0.79
Morphogenesis of flaviviruses. Subcell Biochem (1989) 0.79
Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children. Viral Immunol (1989) 0.79
Human immunologic response to soluble antigens. I. Hypersensitivity induced by a hapten-altered native protein. J Immunol (1970) 0.78
New approaches to flavivirus vaccine development. Biotechnology (1992) 0.78